Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 2/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20815457 | 0.92 | PDE4D (0.44) | PDE4DPTGER2PTGER3PTGER4KCNH2 | |
| SCHEMBL20815455 | 0.92 | PDE4D (0.44) | PDE4DPTGER2PTGER3PTGER4KCNH2 | |
| SCHEMBL20991747 | 0.86 | PTGER2 (0.35) | PDE4DPTGER2PTGER3PTGER4KCNH2 | |
| SCHEMBL20991861 | 0.79 | PDE4D (0.40) | PDE4DPTGER2PTGER3PTGIRPTGER1 | |
| SCHEMBL22278867 | 0.78 | PDE4D (0.39) | PDE4DPTGER2PTGER3PTGIRPTGER1 | |
| SCHEMBL22278903 | 0.78 | PDE4D (0.39) | PDE4DPTGER2PTGER3PTGIRPTGER1 | |
| SCHEMBL22263540 | 0.76 | PDE4D (0.37) | PDE4DPTGER2PTGER3PTGER4PTGIR | |
| SCHEMBL28457532 | 0.76 | PDE4D (0.37) | PDE4DPTGER2PTGER3PTGER4PTGIR | |
| SCHEMBL22263537 | 0.76 | PDE4D (0.37) | PDE4DPTGER2PTGER3PTGER4PTGIR | |
| SCHEMBL20991773 | 0.75 | ALDH1A1 (0.34) | PDE4DPTGER2PTGER3PTGER4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10494338-B2 | Prostaglandin derivative | AGC Inc. (JP) | 2019-12-03 | — | — | US | disclosed |
| US-20190135743-A1 | NOVEL PROSTAGLANDIN DERIVATIVE | AGC Inc. (JP) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10494338-B2 | Prostaglandin derivative | PTGIR, PTGIS, PTGS1 | PDE4D 632/4885PTGER2 10/4885PTGER3 14/4885 |
| US-20190135743-A1 | NOVEL PROSTAGLANDIN DERIVATIVE | PTGIR, PTGIS, PTGER1 | PDE4D 535/4885PTGER2 9/4885PTGER3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.